Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
ADMA STOCK NEWS: ADMA Biologics is Under Investigation for Securities Fraud after Stock Dropped 20%; Contact BFA Law if You Suffered Losses (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?
ADMA is having a stupendous run in 2024 so far on strong performance of Asceniv and high growth prospects.
Adma Biologics (ADMA) Soars 18.8%: Is Further Upside Left in the Stock?
Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Did ADMA Biologics Commit Securities Fraud Resulting in 20% Stock Drop? Contact BFA Law about its Ongoing Securities Fraud Investigation (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ADMA INVESTIGATION NOTE: Contact BFA Law about ADMA Biologics Securities Fraud Investigation into Auditor Resignation (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) concluded the recent trading session at $16.71, signifying a +1.7% move from its prior day's close.
ADMA INVESTIGATION REMINDER: ADMA Biologics Investors are Notified to Contact BFA Law about its Securities Fraud Investigation after Auditor Resigns
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADMA Biologics Inc (ADMA) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc ("ADMA Biologics" or "the Company") (NASDAQ:ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA.
ADMA INVESTIGATION ALERT: Securities Fraud Investigation into ADMA Biologics after Auditor Resigns is Ongoing; Investors with Losses are Reminded to Contact BFA Law
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
